.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,323,205

« Back to Dashboard

Details for Patent: 6,323,205

Title: Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
Abstract:Preliminary clinical studies in humans have now been done which show both the efficacy of 10-propargyl-10dAM and a preferred dosage schedule for such treatments. In addition, it has now been determined that combinations of 10-propargyl-10-deazaaminopterin (preferably highly purified forms, substantially free of 10-deazaaminopterin) with taxols exhibit synergistic effectiveness in the treatment of tumors. 10-propargyl-10-deazaaminopterin and a taxol in therapeutically effective amounts can be administered concurrently, one right after the other, or with a period of time in between.
Inventor(s): Sirotnak; Francis M. (New York, NY), Piper; James R. (Birmingham, AL), DeGraw; Joseph I. (Missoula, MT), Colwell; William T. (Menlo Park, CA)
Assignee: Sloan-Kettering Institute for Cancer Research (New York, NY) SRI International (Menlo Park, CA) Southern Research Institute (Birmingham, AL)
Filing Date:Feb 17, 2000
Application Number:09/505,571
Claims:1. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias.

2. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.

3. The method of claim 1, wherein the tumor is a solid tumor.

4. The method of claim 3, wherein the tumor is a mammary tumor.

5. The method of claim 3, wherein the tumor is a lung tumor.

6. The method of claim 3, wherein the tumor is a prostate tumor.

7. The method of claim 1, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.

8. The method of claim 1, wherein the taxane is administered immediately following the 10-propargyl-10-deazaaminopterin.

9. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.

10. The method of claim 8, wherein the tumor is a solid tumor.

11. The method of claim 10, wherein the tumor is a mammary tumor.

12. The method of claim 10, wherein the tumor is a lung tumor.

13. The method of claim 10, wherein the tumor is a prostate tumor.

14. The method of claim 8, wherein the 10-propargyl-10-deazaaminopterin is administered biweekly.

15. A method for treatment of tumors comprising administering to a human patient diagnosed as having a tumor a therapeutically effective amount of 10-propargyl-10-deazaaminopterin, wherein the 10-propargyl-10-deazaaminopterin is administered in biweekly doses, and wherein the tumor is selected from the group consisting of mammary tumors, lung cancer, prostate cancer and leukemias.

16. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is administered in an amount of 150 mg/m.sup.2 /biweekly dose.

17. The method of claim 15, wherein the 10-propargyl-10-deazaaminopterin is substantially free of 10-deazaaminopterin.

18. A method for treatment of tumors comprising administering to a patient diagnosed as having a tumor therapeutically effective amounts of 10-propargyl-10-deazaaminopterin and a taxane, wherein the tumors are selected from among tumors expressing folyl polyglutamate synthetase and wherein the folyl polyglutamate synthetase is effective to catalyze the polyglutamylation of the 10-propargyl-10-deazaaminopterin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc